This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
ACC/AHA 2025 hypertension guidelines: what's new?
Check out the summary on AHA/ACC hypertension guidelines chat, done by NephJC intern Sridatta Pawar

